Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Agenus

Agenus

An immuno-oncology company developing treatments for cancer

Help us improve this page by adding information.
Visit our Writing Guide or this topic page for additional help.

Timeline

December 1, 2020
Agenus launches phase 2 trial expansion in Colon Cancer for AGEN1181 in Combination with BalstilimabNew objective response in colon cancer triggers trial expansion.

Funding Rounds

Products

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date

News

Title
Author
Date
Publisher
Description
Nick Paul
August 27, 2021
FierceBiotech
Agenus is now in the closing stretch of its multidecade effort to bring a drug to market. With the FDA set to decide whether to approve PD-1 drug balstilimab in December, Agenus has published the phase 2 data it hopes will secure authorization in cervical cancer.
Brandon May
July 8, 2021
BioSpace
Agenus, an immuno-oncology company based out of Lexington, Mass., has purchased a 120-acre plot of land near Genentech's manufacturing facility in Vacaville, Cali.
Mark Terry
May 19, 2021
BioSpace
BMS inked a collaboration agreement with Exscientia that can leverage AI to speed the discovery of drug candidates in therapeutic areas, including oncology and immunology.
Mark Terry
May 18, 2021
BioSpace
Under the terms of the agreement, Bristol Myers Squibb will take over complete responsibility for the development and commercialization of AGEN1777 and any related products globally.
Ben Adams
May 18, 2021
FierceBiotech
Bristol Myers Squibb, looking to the future beyond Opdivo, has penned a major biobucks pact for two early-stage assets out of small biotech Agenus.
SHOW MORE

References

Golden logo
By using this site, you agree to our Terms & Conditions.